Summary
Brazil experienced moments of collapse in its health system throughout 2021, driven by a timid initial vaccination strategy against Covid-19, combined with the emergence of variants of interest (VOC). Mathematical modelling has been used to subsidize decision-makers in public health planning. Considering the vaccine products available, effectiveness estimates, the emergence of Gamma as the predominant VOC circulating in 2021, and national estimated doses available for the next several months, we developed a Markov-chain mathematical modelling approach to evaluate optimal strategies for Covid-19 vaccination in Brazil in terms of Covid deaths averted. Our main findings are that in order to reach higher vaccination impact in Brazil, Covid-19 immunization strategies should include recovering vaccination coverage rates in high-risk groups reaching higher coverage; expanding vaccination to younger age groups should be considered only after ensuring at least 80% coverage in older age groups; reducing the interval between doses of AZD1222 from 12 to 8 weeks. We also demonstrate that the latter is only feasible if accompanied by an increase in vaccine supply of at least 50% in the next six month period.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the Brazilian National Council for Scientific and Technological Development (CNPq) - Process # 402834/2020-8 (request for proposals MCTIC/CNPq/FNDCT/MS/SCTIE/Decit N° 07/2020). The funding sources played no role in the study design, collection, analysis, or interpretation of the data, writing the report, or deciding to submit the paper for publication. LSF received a master's scholarship from Coordination of Superior Level Staff Improvement (CAPES) (finance code 001). GBA received a technological and industrial scholarship from CNPq (grant number 301796/2021-1). MEB received a technological and industrial scholarship from CNPq (grant number 315854/2020-0). LMS received a technological and industrial scholarship from CNPq (grant number 315866/2020-9). SP was supported by São Paulo State Research Support Foundation (FAPESP) (grant number: 2018/24037-4). AMB received a technological and industrial scholarship from CNPq (grant number 402834/2020-8). MQMR received a postdoctoral scholarship from CAPES (grant number 305269/2020-8). RSK has been supported by CNPq (proc. 312378/2019-0). JAFD-F has been supported by the CNPq productivity fellowship and the National Institutes for Science and Technology in Ecology, Evolution and Biodiversity Conservation (INCT-EEC), supported by MCTIC/CNPq (proc. 465610/2014-5) and FAPEG (proc. 201810267000023). RAK has been supported by CNPq (grant number: 311832/2017-2) and FAPESP (contract number: 2016/01343-7). CMT has been supported by the CNPq productivity fellowship and the National Institute of Science and Technology for Health Technology Assessment (IATS) (proc: 465518/2014-1).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The authors state that the database used in the analyses are available as a supplementary file to the paper and can be provided to interested researchers upon reasonable request.
